Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision: v3.6.6 is now shown on the page, replacing the previous v3.6.5. This indicates a minor update to the page's revision metadata rather than a substantive change to the study content.
    Difference
    0.1%
    Check dated 2026-09-01T18:26:00.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.6.5 instead of v3.6.4, indicating a small system update; no clinical trial details or navigation changes are affected.
    Difference
    0.1%
    Check dated 2026-08-11T17:23:36.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.3 to v3.6.4, a maintenance update that does not change substantive content.
    Difference
    0.1%
    Check dated 2026-07-28T05:59:42.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page now lists Revision: v3.6.3 for the Study Protocol and Statistical Analysis Plan, replacing v3.6.2. This indicates the linked documentation has been updated to the latest version.
    Difference
    0.1%
    Check dated 2026-07-06T16:40:05.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.6.0 to v3.6.2, indicating a newer revision of the document. No visible content or feature changes are indicated by the provided data.
    Difference
    0.1%
    Check dated 2026-06-29T08:53:02.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    No additions or deletions were provided, so there are no changes to evaluate. The page's described content remains as in the full context, including the study details.
    Difference
    0.2%
    Check dated 2026-06-22T09:44:02.000Z thumbnail image

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.